ArticleScientific reports2025
125I inhibits the progression of cervical cancer by upregulating the HSF1/PU.1/SYK signaling pathway and consequently enhancing the apoptotic response mediated by ROS/USP7/P53.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mitochondrial reprogramming in cervical cancer: crosstalk with tumor immunity, HPV oncogenic signaling, and therapeutic resistance.Frontiers in immunology · 2026Review
- Efficacy and safety of anlotinib combined withFrontiers in endocrinology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
125I (iodine-125) is a radioactive isotope commonly used in the treatment of cervical cancer, especially in brachytherapy. This study investigates the molecular mechanism by which 125I radiotherapy inhibits the progression of cervical cancer. C33A cervical cancer cells were subjected to irradiation with 125I. Subsequently, lentiviral infection was utilized to overexpress and knock down HSF1, as well as to overexpress PU.1. The efficiency of gene knockdown was evaluated via qPCR experiments, followed by treatment with the SYK inhibitor R406. Immunofluorescence staining was employed to determine the relative fluorescence intensity of HSF1 and P53. The relative protein expression levels of HSF1, PU.1, SYK, Dectin-1, and P53 were assessed using flow cytometry to examine apoptosis in C33A cells. Cell viability and proliferative capacity were measured using CCK-8 assays and colony formation assays. The progression of cervical cancer was evaluated through subcutaneous xenograft tumor experiments in nude mice. Transwell and scratch assays were conducted to assess the invasive and migratory capabilities of C33A cells. 125I radiotherapy can augment the expression of HSF1, PU.1, SYK, Dectin-1, β3-integrin, P22, P47, P53, gp91, and p-USP7 in C33A cells. In subcutaneous xenograft tumor experiments conducted in nude mice, 125I radiotherapy also facilitates apoptosis in C33A cells, curtails their viability, proliferative potential, and invasive and migratory capacities, thereby mitigating the progression of cervical cancer. However, specific knockdown of HSF1 and the administration of the SYK inhibitor R406 can reverse the potentiating effect of 125I radiotherapy on the ROS/USP7/P53 pathway, consequently promoting the progression of cervical cancer; specific overexpression of PU.1 can abrogate the inhibitory impact of HSF1 knockdown on the ROS/USP7/P53 pathway, thereby suppressing the progression of cervical cancer. 125I inhibits the progression of cervical cancer by upregulating the HSF1/PU.1/SYK signaling pathway and consequently enhancing the apoptotic response mediated by ROS/USP7/P53.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.